Walkersville, MD (USA) / Basel, Switzerland, 15 August 2017 – Today Lonza announced an endothelial cell application center, which expands Lonza’s support for researchers. This new online suite provides scientists with educational materials and product information to assist with vital endothelial cell research. As endothelial cells regulate many homeostatic processes within the body, their dysfunction has important implications for diseases, such as diabetes, cardiovascular disease and cancer. Increasing our understanding of endothelial cells could help researchers to develop more effective drugs to treat these diseases.

Lonza’s easy-to-navigate endothelial cell application center is categorized by research area and can be accessed online anytime and anywhere, making it a handy tool for scientists to use on-demand. The center provides a comprehensive portal of support resources, including technical whitepapers, research publications and product information for applications ranging from inflammation and angiogenesis to cardiovascular disease. 

As endothelial cells are particularly hard to co-culture, Lonza’s...

Lubna Hussain, Senior Global Product Manager for Primary Cells, Lonza, said: “Lonza is committed to supporting the work of scientists and with endothelial cells playing a crucial role in the pathology and treatment of many diseases, we felt it was important to create a centralized portal of materials to assist this research. Resources in our new application center can be viewed online from anywhere and are free to download.”

Lonza offers an extensive range of authenticated, ready-to-use human primary endothelial cells. The portfolio contains more than 30 varieties of human primary endothelial cells from tissue sources ranging from heart, lung, and skin, to the reproductive organs, and includes cells from type I and type II diabetic donors.

To access the endothelial cell application center, please visit http://www.lonza.com/endothelial-cell-application-center. Special terms of use may apply.

About Lonza 

Following the closing of the Capsugel acquisition, Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?